

RETRACTION NOTE **OPEN**

Retraction Note: Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy

V. La, R. Fujikawa, D. M. Janzen, M. Nunez, L. Bainvoll, L. Hwang, K. Faull, G. Lawson and S. Memarzadeh

npj Precision Oncology (2021)5:77 ; <https://doi.org/10.1038/s41698-021-00217-9>

Retraction of: *npj Precision Oncology* <https://doi.org/10.1038/s41698-017-0008-z>, published online 03 April 2017

This Article¹ has been retracted by the Authors because concerns have been raised regarding the identity of the cell lines used for the experimental work. Specifically, re-analysis showed that the S1GODL xenografts matched STR profiles of Ovar-3 cells, and review of raw flow cytometry data was found to be discordant with presented data. In light of these findings, the identity of the cells within the experimental groups in the manuscript is uncertain, and the conclusions of the work are not reliable.

Authors Vincent La, Rachel Fujikawa, Deanna Janzen, Miguel Nunez, Lin Hwang, Kym Faull, Greg Lawson, and Sanaz Memarzadeh agree with this attraction. Liat Bainvoll did not respond to correspondence from the Publisher about this retraction.

REFERENCE

1. La, V. et al. Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy. *npj Precision Onc.* **1**, 7, <https://doi.org/10.1038/s41698-017-0008-z> (2017).

ADDITIONAL INFORMATION

Correspondence and requests for materials should be addressed to S.M.

Reprints and permission information is available at <http://www.nature.com/reprints>



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021